Bhavana Konda, MD, MPH, Section Chief, Neuroendocrine Tumors and Endocrine Medical Oncology at The Ohio State University Comprehensive Cancer Center. (IMAGE)
Caption
“This trial is evaluating a new approach for patients diagnosed with a condition that has few available treatments,” said Alliance study chair Bhavana Konda, MD, MPH, Section Chief, Neuroendocrine Tumors and Endocrine Medical Oncology at The Ohio State University Comprehensive Cancer Center. “We’re investigating whether a combination of targeted therapy and immunotherapy may improve disease control and improve quality of life for patients with this condition.”
Credit
Courtesy The Ohio State University
Usage Restrictions
none
License
Original content